Effects of Hepatitis B Virus Infection Prognosis to Non-Small Cell Lung Cancer Survival
Celal Alandag1, Egemen Konak2, Sami Fidan3, Evren Kara Fidan41Department of Medical Oncology, Sivas Numune Hospital, Sivas, Türkiye, 2Department of Internal Medicine, Karadeniz Technical University, Trabzon, Türkiye, 3Department of Gastroenterology, Karadeniz Technical University, Trabzon, Türkiye, 4Department of Medical Oncology, Karadeniz Technical University, Trabzon, Türkiye
Objectives: Hepatitis B virus (HBV) infection and non-small cell lung cancer are both common diseases. These two diseases can often coexist. We planned to investigate the effects of HBV infection prognosis on NSCLC patients' overall survival (OS) times. Methods: It was a retrospective study. The files of NSCLC patients who applied to our oncology department between January 2012 and December 2018 were scanned. Patients were divided into four groups in terms of HBV infection status; chronic Hepatitis B, hepatitis B recovery, vaccinated, and never HBV infected groups. All groups were compared for their OS times. Results: Median OS was 12.86 months (95% confidence interval (CI), 10.54-15.18) for the whole group. Median OS times of not infected with HBV, spontaneous recovery, vaccinated, and chronic hepatitis B were 10.63, 13.03, 16.36, 7.16 months, respectively. There weren’t any statistically meaningful differences between groups in terms of OS. Conclusion: We hypothesized that the immune system might be more robust in patients with HBV spontaneous seroclearance (recovery) and the median OS might be better in metastatic NSCLC patients. This study's results did not meet our hypothesis. But the HBV vaccination ratio of patients was only 5.7%. In future studies effects of HBV vaccination to NSCLC prognonsis should be studied conducted more HBV vaccinated patient rate. Keywords: Hepatitis B, prognosis, survival, non-small cell lung cancer
Cite This Article
Alandag C, Konak E, Fidan S, Fidan E. Effects of Hepatitis B Virus Infection Prognosis to Non-Small Cell Lung Cancer Survival. EJMI. 2022; 6(3): 332-334
Corresponding Author: Celal Alandag